Introductions
What is ALGYL GGP?
Algyl GGP is a combination of four substances: hyaluronic acid (in the form of sodium hyaluronate), glycine, proline, and N-acetylglucosamine. These ingredients are processed into a gel structure using a patented unique technology. The product is intended for intra-articular injection treatment of osteoarthritis, to increase joint viscoelasticity and support the reconstruction of articular cartilage.
MORE
Composition
The composition
targets pathogenic factors
In the pathogenesis of osteoarthritis, a key role is played by the predominance of hyaluronic acid catabolism over its production and the reduced synthesis of collagen, a fundamental component of articular cartilage. Based on these insights, the formulation of the product was developed: hyaluronic acid is complemented by substances that support cartilage regeneration and ensure a long-lasting effect.
Hyaluronic Acid
- Improves the viscosity of synovial fluid
- Stimulates chondrocytes to increase endogenous synthesis of glycosaminoglycans
- Acts as an analgesic by coating nociceptors and reducing the production of nociceptive mediators
- Reduces the production of inflammatory mediators
Glycine
- An amino acid essential for collagen synthesis, representing every third amino acid residue in its structure
- Necessary for the formation of a stable triple-helix structure of collagen
- A component of the proteoglycan lubricin, important for joint lubrication and shock absorption
- Exhibits anti-inflammatory and antioxidant effects
Proline
- An amino acid essential for collagen synthesis in chondrocytes
- Important not only for collagen synthesis but also for other substances crucial to the physiological condition of connective tissue
- Has anti-inflammatory, analgesic, and immunomodulatory effects
- Supports the proliferation and differentiation of chondrocytes, contributing to the regulation of bone metabolism balance
N-acetylglucosamine
- Supports cartilage regeneration by activating the synthesis of proteoglycans and glycosaminoglycans in chondrocytes
- Inhibits matrix metalloproteinases
- Promotes the biosynthesis of hyaluronic acid
- Reduces the production of pro-inflammatory mediators
Effect
Short-term and long-term effect
Benefits compared to monocomponent products
Monocomponent hyaluronic acid provides only short-term pain relief and functional improvement, whereas Algyl GGP, thanks to its composition, delivers a dual effect:
Hyaluronic acid creates optimal intra-articular fluid viscosity through viscosupplementation.
Glycine + proline increase the production of collagen and the proteoglycan lubricin. N-acetylglucosamine activates the synthesis of other essential cartilage components (proteoglycans and glycosaminoglycans). The synergistic action of these substances results in cartilage regeneration and reconstruction, along with viscoelastic restoration of synovial fluid.
Studies
Efficacy and Safety
A laboratory study demonstrated that Algyl GGP is significantly more effective in treating knee osteoarthritis than monocomponent hyaluronic acid or saline solution, and leads to the regression of degenerative cartilage changes.⁶
In orthopedic practice, Algyl GGP has been tested on more than 200,000 patients with gonarthrosis and has proven to be effective and safe, with a long-lasting effect. A safety report confirms that no adverse effects—such as joint pain or swelling, injection site reactions, or other complications—were observed during application.
Fig. 1. Group with induced osteoarthritis after saline application: cartilage sections show irregularities and erosions caused by osteoarthritis.
Fig. 2. Group with induced osteoarthritis after hyaluronic acid application: cartilage surface is uneven, erosions extend into the subchondral bone, and inflammatory cells are present.
Fig. 3. Group with induced osteoarthritis after application of Algyl GGP: cartilage surface is smooth, indicating ongoing regeneration.
Application
APPLICATION PROCEDURE
-
Algyl GGP is administered once every 6, 12, or 16 months, depending on the severity of the condition; a second dose may be applied if necessary.
In the presence of joint effusion, it is recommended to reduce it by aspiration of the exudate, rest, cold compress application, and/or intra-articular corticosteroid injection. The application of Algyl GGP should follow 2–3 days later. -
Based on clinical experience, Algyl GGP can be administered in multiple joints simultaneously, and therapeutic cycles may be repeated as required.
For cartilage tissue reconstruction, Algyl GGP can be combined with the medical device CHondroGrid. To strengthen weakened and hypermobile joint systems (ligaments, tendons, joint capsules), it is advisable to combine it with the medical device Guna MD-Tissue. -
Product classification: Class III Medical Device
-
Storage conditions: 2 °C – 25 °C
23.2.2026
NEW: ALGYL CBD Pain Relief Patch – modern topical pain relief with CBD, arnica, and menthol
Muscle and joint pain is among the most common problems in everyday life. It can occur after physical strain, during sports, after injuries, or in connection with chronic musculoskeletal conditions. Many people therefore look for an effective, locally applicable, and well-tolerated solution that does not unnecessarily burden the body. The ALGYL CBD Pain Relief Patch was developed precisely for this need. It is a locally applied patch containing a combination of cannabidiol (CBD), menthol, and arnica. The formula is designed to target pain directly at the affected area while allowing practical use in everyday life.
more
27.2.2025
ALGYL GGP - PRODUCT PROFILE
Osteoarthritis (OA) is a degenerative joint disease whose incidence increases with rising average age. It therefore represents a growing challenge for orthopedic practice. In recent years, treatment of this disease has focused not only on pain relief, but also on slowing the progression of cartilage degeneration. In the treatment of OA, intra-articular administration of active substances directly into the affected joint has an important role. Since 2024, the innovative product Algyl GGP has been available in several EU countries (CZ, SK, DE, AT, IT); its concept is based on the latest scientific knowledge of the etiopathogenesis of this disease.
more